Effects of metformin withdrawal after long and short term treatment in PCOS: observational longitudinal study

Nika Aleksandra Kravos, Andrej Janež, Katja Goričar, Vita Dolžan, Mojca Jensterle, Nika Aleksandra Kravos, Andrej Janež, Katja Goričar, Vita Dolžan, Mojca Jensterle

Abstract

Background: Metformin plays a consolidated role in the management of polycystic ovary syndrome (PCOS). However, there is no clear answer on how long we should treat and on how long its beneficial impact sustain after we stop treatment. We compared the effects of metformin withdrawal after long-term (LT) and short term (ST) treatment in PCOS women that had previously well responded to metformin.

Methods: We conducted observational longitudinal study including 44 PCOS women (31 (28-36) years and BMI 32.5 (27.7-34.9) kg/m2) that were followed for 6 months after metformin withdrawal. Prior inclusion, ST group had been treated with metformin on average for 1.03 ± 0.13 year, LT group for 5.07 ± 2.52 years. We followed anthropometric, metabolic, reproductive parameters and eating behavior as assessed by TFEQ-R18.

Results: After metformin withdrawal, ST group gained significant amount of weight (from 92 (75.5-107.3) kg to 96 (76-116) kg; p = 0.019). Weight tended to increase also in LT users (from 87 (75-103) to 87 (73-105) kg; p = 0.058). More women in LT group maintained stable weight (27% in LT group vs 15% in ST group). Eating behavior deteriorated in both groups. Withdrawal of metformin resulted in a decrease of menstrual frequency (6 (6-6) to 6 (4-6) menstrual bleeds per 6 months; p = 0.027) and in borderline increase of androstenedione (6.4 (4.6-7.6) to 7.8 (4.8-9.6) nmol/L; p = 0.053) in LT group. Waist circumference, HOMA and glucose homeostasis remained stable in both groups. There were no differences between groups at 6-month follow up.

Conclusion: Collectively, present study implies some metabolic and endocrine treatment legacy in both groups as well as some group-specific deteriorations in clinical parameters 6 months after metformin withdrawal.

Trial registration: The study is registered at Clinical Trials with reference No. NCT04566718.

Keywords: Legacy; Metformin; Obesity; PCOS.

Conflict of interest statement

The authors declare that they have no competing interest.

References

    1. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, International PCOS Network et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602–1618. doi: 10.1093/humrep/dey256.
    1. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Endocrine Society et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–92. doi: 10.1210/jc.2013-2350.
    1. Yang PK, Hsu CY, Chen MJ, Lai MY, Li ZR, Chen CH, et al. The Efficacy of 24-Month Metformin for Improving Menses, Hormones, and Metabolic Profiles in Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2018;103(3):890–899. doi: 10.1210/jc.2017-01739.
    1. Sharma N, Siriesha LY, Kaur A, Ahuja VK. Effect of metformin on insulin levels, blood sugar, and body mass index in polycystic ovarian syndrome cases. J Family Med Prim Care. 2019;8(8):2691–2695.
    1. Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol. 2010;162(2):193–212. doi: 10.1530/EJE-09-0733.
    1. Diabetes Prevention Program Research Group Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012;35(4):731–737. doi: 10.2337/dc11-1299.
    1. Ramezani Tehrani F, Amiri M, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol. 2020;36(1):12–23. doi: 10.1080/09513590.2019.1650337.
    1. Palomba S, Falbo A, Zullo F, Orio F., Jr Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev. 2009;30(1):1–50. doi: 10.1210/er.2008-0030.
    1. Sharma ST, Wickham EP, 3rd, Nestler JE. Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: a retrospective analysis. Endocr Pract. 2007;13(4):373–379. doi: 10.4158/EP.13.4.373.
    1. Indonesian Diabetes Association Guidelines on the management and prevention of prediabetes. Acta Med Indones. 2014;46(4):348–359.
    1. Palomba S, Falbo A, Russo T, Manguso F, Tolino A, Zullo F, et al. Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92(8):3128–3135. doi: 10.1210/jc.2007-0441.
    1. Glueck CJ, Aregawi D, Agloria M, Winiarska M, Sieve L, Wang P. Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome. Metabolism. 2006;55(12):1582–1589. doi: 10.1016/j.metabol.2006.08.001.
    1. Jensterle M, Kravos NA, Ferjan S, Goricar K, Dolzan V, Janez A. Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort. Endocr Connect. 2020;9(1):44–54. doi: 10.1530/EC-19-0449.
    1. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) Hum Reprod. 2004;19(1):41–47. doi: 10.1093/humrep/deh098.
    1. Azziz R. Introduction: determinants of polycystic ovary syndrome. Fertil Steril. 2016;106(1):4–5. doi: 10.1016/j.fertnstert.2016.05.009.
    1. de Lauzon B, Romon M, Deschamps V, Lafay L, Borys JM, Karlsson J, Fleurbaix Laventie Ville Sante Study Group et al. The Three-Factor Eating Questionnaire-R18 is able to distinguish among different eating patterns in a general population. J Nutr. 2004;134(9):2372–80. doi: 10.1093/jn/134.9.2372.
    1. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419. doi: 10.1007/BF00280883.
    1. Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmö. Sweden. Diabet Med. 2000;17(4):299–307. doi: 10.1046/j.1464-5491.2000.00280.x.
    1. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Expert Committee on the Diagnosis and Classification of Diabetes Mellitus et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160–7. doi: 10.2337/diacare.26.11.3160.
    1. Stunkard AJ, Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res. 1985;29(1):71–83. doi: 10.1016/0022-3999(85)90010-8.
    1. Lentferink YE, Knibbe CAJ, van der Vorst MMJ. Efficacy of metformin treatment with respect to weight reduction in children and adults with obesity: a systematic review. Drugs. 2018;78(18):1887–1901. doi: 10.1007/s40265-018-1025-0.
    1. Romualdi D, De Marinis L, Campagna G, Proto C, Lanzone A, Guido M. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism. Clin Endocrinol (Oxf) 2008;69(4):562–567. doi: 10.1111/j.1365-2265.2008.03204.x.
    1. Yerevanian A, Soukas AA. Metformin: mechanisms in human obesity and weight loss. Curr Obes Rep. 2019;8(2):156–164. doi: 10.1007/s13679-019-00335-3.
    1. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 1996;335(9):617–623. doi: 10.1056/NEJM199608293350902.
    1. Kim CH, Chon SJ, Lee SH. Effects of lifestyle modification in polycystic ovary syndrome compared to metformin only or metformin addition: a systematic review and meta-analysis. Sci Rep. 2020;10(1):7802. doi: 10.1038/s41598-020-64776-w.
    1. Roseff S, Montenegro M. Inositol treatment for PCOS should be science-based and not arbitrary. Int J Endocrinol. 2020;27(2020):6461254.
    1. Ferjan S, Janez A, Jensterle M. DPP4 inhibitor sitagliptin as a potential treatment option in metformin-intolerant obese women with polycystic ovary syndrome: a pilot randomized study. Endocr Pract. 2018;24(1):69–77. doi: 10.4158/EP-2017-0027.
    1. Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reprod Biomed Online. 2019;39(2):332–342. doi: 10.1016/j.rbmo.2019.04.017.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren